Literature DB >> 32911135

The potential utility of anterior upper lobe honeycomb-like lesion in interstitial lung disease associated with connective tissue disease.

Hideaki Yamakawa1, Takashi Ogura2, Shintaro Sato3, Tomotaka Nishizawa4, Rie Kawabe5, Tomohiro Oba6, Akari Kato7, Masanobu Horikoshi8, Keiichi Akasaka9, Masako Amano10, Kazuyoshi Kuwano11, Hiroki Sasaki12, Tomohisa Baba13, Hidekazu Matsushima14.   

Abstract

BACKGROUND: Interstitial lung disease (ILD) is associated with high morbidity and mortality in patients with connective tissue disease (CTD). Because some patients with CTD overlap present with ILD first, with CTD diagnosed later, specific radiologic signs are needed to help differentiate each CTD or CTD-ILD from idiopathic ILD.
OBJECTIVES: To determine whether specific CT findings can help differentiate CTD as rheumatoid arthritis (RA), systemic sclerosis (SSc), or polymyositis/dermatomyositis (PM/DM).
METHODS: We analyzed 143 consecutive ILD patients with RA, SSc, or PM/DM. We assessed diagnostic accuracy of CT findings of CTD-ILD, CT pattern, and signs including "anterior upper lobe honeycomb-like lesion" and "low attenuation area (LAA) within an interstitial abnormality" for each CTD-ILD. Prognostic predictors were determined using Cox regression models.
RESULTS: Subjects were 78 patients with RA-ILD, 38 with SSc-ILD, 24 with PM/DM-ILD, and 3 with overlapping CTD-ILD. High frequency of anterior upper lobe honeycomb-like lesion suggests that CTD-ILD is due to RA-ILD (22%) rather than SSc-ILD (8%) or PM/DM-ILD (8%), whereas LAA within an interstitial abnormality suggests that CTD-ILD is due to SSc-ILD (26%) rather than RA-ILD (4%) or PM/DM-ILD (0%). Multivariate analysis showed that while not associated with survival, current or ex-smoker, honeycombing, and acute exacerbation were negative prognostic factors of mortality.
CONCLUSIONS: The tendency is high for RA-ILD, in which anterior upper lobe honeycomb-like lesion is a specific feature, to show UIP or NSIP/UIP pattern, combined emphysema, and honeycombing; SSc-ILD to show NSIP pattern and LAA within an interstitial abnormality; and PM/DM-ILD to show NSIP pattern and non-honeycombing.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anterior upper lobe honeycomb-like lesion; Connective tissue disease; Interstitial lung disease; Rheumatoid arthritis

Mesh:

Year:  2020        PMID: 32911135     DOI: 10.1016/j.rmed.2020.106125

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

1.  The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study.

Authors:  Jiaqi Wang; Xiao Wang; Xiaoyan Qi; Zhijian Sun; Tao Zhang; Yi Cui; Qiang Shu
Journal:  Front Med (Lausanne)       Date:  2022-05-12

2.  Prognostic value of radiological findings indeterminate for UIP pattern and anterior upper lobe honeycomb-like lesion in chronic fibrosing interstitial lung disease associated with MPO-ANCA.

Authors:  Hideaki Yamakawa; Shintaro Sato; Tomohiko Nakamura; Tomotaka Nishizawa; Rie Kawabe; Tomohiro Oba; Masanobu Horikoshi; Keiichi Akasaka; Masako Amano; Kazuyoshi Kuwano; Hiroki Sasaki; Hidekazu Matsushima
Journal:  BMC Pulm Med       Date:  2021-11-03       Impact factor: 3.317

Review 3.  Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management.

Authors:  Hongseok Yoo; Takuya Hino; Jiwon Hwang; Teri J Franks; Joungho Han; Yunjoo Im; Ho Yun Lee; Man Pyo Chung; Hiroto Hatabu; Kyung Soo Lee
Journal:  Eur J Radiol Open       Date:  2022-04-07

Review 4.  Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review.

Authors:  Hideaki Yamakawa; Yuko Toyoda; Tomohisa Baba; Tomoo Kishaba; Taiki Fukuda; Tamiko Takemura; Kazuyoshi Kuwano
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.